227 related articles for article (PubMed ID: 21188640)
1. Acromegaly as a cause of 1,25-dihydroxyvitamin D-dependent hypercalcemia: case reports and review of the literature.
Shah R; Licata A; Oyesiku NM; Ioachimescu AG
Pituitary; 2012 Dec; 15 Suppl 1():S17-22. PubMed ID: 21188640
[TBL] [Abstract][Full Text] [Related]
2. Hypercalcemia in a patient with primary hyperparathyroidism and acromegaly: distinct roles of growth hormone and parathyroid hormone in the development of hypercalcemia.
Ueda M; Inaba M; Tahara H; Imanishi Y; Goto H; Nishizawa Y
Intern Med; 2005 Apr; 44(4):307-10. PubMed ID: 15897641
[TBL] [Abstract][Full Text] [Related]
3. Hypercalcemia and acromegaly--clarifying the connections. A case report and review of the literature.
Manroa P; Kannan S; Hatipoglu B; Licata A
Endocr Pract; 2014 May; 20(5):e86-90. PubMed ID: 24449661
[TBL] [Abstract][Full Text] [Related]
4. Acromegaly and non-parathyroid hormone-dependent hypercalcemia: a case report and literature review.
Shi S; Zhang L; Yu Y; Wang C; Li J
BMC Endocr Disord; 2021 May; 21(1):90. PubMed ID: 33933067
[TBL] [Abstract][Full Text] [Related]
5. Gestational hypercalcemia: Prevalence and biochemical profile.
Schoenmakers I; Piec I; Baban S; Bärebring L; Green D; Washbourne CJ; Tang JCY; Fraser WD; Augustin H
J Steroid Biochem Mol Biol; 2020 May; 199():105611. PubMed ID: 32007562
[TBL] [Abstract][Full Text] [Related]
6. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
[TBL] [Abstract][Full Text] [Related]
7. 1,25-dihydroxyvitamin D suppresses circulating levels of parathyroid hormone in a patient with primary hyperparathyroidism and coexistent sarcoidosis.
Kinoshita Y; Taguchi M; Takeshita A; Miura D; Tomikawa S; Takeuchi Y
J Clin Endocrinol Metab; 2005 Dec; 90(12):6727-31. PubMed ID: 16159932
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.
Tebben PJ; Singh RJ; Kumar R
Endocr Rev; 2016 Oct; 37(5):521-547. PubMed ID: 27588937
[TBL] [Abstract][Full Text] [Related]
9. Sarcoidosis within a pituitary adenoma.
Rubin MR; Bruce JN; Khandji AG; Freda PU
Pituitary; 2001 Aug; 4(3):195-202. PubMed ID: 12138993
[TBL] [Abstract][Full Text] [Related]
10. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.
Parkinson C; Kassem M; Heickendorff L; Flyvbjerg A; Trainer PJ
J Clin Endocrinol Metab; 2003 Dec; 88(12):5650-5. PubMed ID: 14671148
[TBL] [Abstract][Full Text] [Related]
11. Safety of megadose of vitamin D in patients with nephrolithiasis.
de Carvalho JF; Churilov LP
Nutrition; 2021; 87-88():111201. PubMed ID: 33744642
[TBL] [Abstract][Full Text] [Related]
12. Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism.
Christensen SE; Nissen PH; Vestergaard P; Heickendorff L; Rejnmark L; Brixen K; Mosekilde L
Eur J Endocrinol; 2008 Dec; 159(6):719-27. PubMed ID: 18787045
[TBL] [Abstract][Full Text] [Related]
13. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
[TBL] [Abstract][Full Text] [Related]
14. Suppressibility of parathyroid hormone in primary hyperparathyroidism.
Khoo TK; Baker CH; Abu-Lebdeh HS; Wermers RA
Endocr Pract; 2007; 13(7):785-9. PubMed ID: 18194938
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of acromegaly in a patient with type 1 diabetes mellitus.
Hofmann EA; Polonsky KS; Weiss RE
Endocr Pract; 2002; 8(2):113-8. PubMed ID: 11942776
[TBL] [Abstract][Full Text] [Related]
16. Changes in calcium homeostasis in acromegaly treated by pituitary adenomectomy.
Takamoto S; Tsuchiya H; Onishi T; Morimoto S; Imanaka S; Mori S; Seino Y; Uozumi T; Kumahara Y
J Clin Endocrinol Metab; 1985 Jul; 61(1):7-11. PubMed ID: 3839000
[TBL] [Abstract][Full Text] [Related]
17. Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly.
Arihara Z; Sakurai K; Yamashita R; Niitsuma S; Ueno T; Yamamura N; Yamada S; Inoshita N; Takahashi K
Tohoku J Exp Med; 2014 Oct; 234(2):129-35. PubMed ID: 25253414
[TBL] [Abstract][Full Text] [Related]
18. Hypercalcemia in non-Hodgkin's lymphoma due to cosecretion of PTHrP and 1,25-dihydroxyvitamin D.
Gonciulea AR; Wang Y; Bikle DD; Sellmeyer DE
Osteoporos Int; 2021 Dec; 32(12):2587-2592. PubMed ID: 34230999
[TBL] [Abstract][Full Text] [Related]
19. Differential diagnosis of vitamin D-related hypercalcemia using serum vitamin D metabolite profiling.
Kaufmann M; Schlingmann KP; Berezin L; Molin A; Sheftel J; Vig M; Gallagher JC; Nagata A; Masoud SS; Sakamoto R; Nagasawa K; Uesugi M; Kottler ML; Konrad M; Jones G
J Bone Miner Res; 2021 Jul; 36(7):1340-1350. PubMed ID: 33856702
[TBL] [Abstract][Full Text] [Related]
20. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
